Answers are grounded in this paper and cite their sources.
Endoscopic sequential therapy for portal hypertension: Concept and clinical efficacy *Variceal bleeding is the most dreadful complication of liver cirrhosis and adversely affected 6.8 million people worldwide in 2017, with up to 80% 5-year mortality.1,2 Endoscopic therapies have played a pivotal role in the management of variceal bleeding for more than three decades, and in recent years, the rebleeding rate and bleeding-related mortality at 1 year have been reduced from 60% to 30% and 50% to 15e20%, respectively.3e5 Complete eradication of esophageal varices (EV), which can be obtained by repeated sessions of operational endoscopies, was recommended as the therapeutic goal of endoscopic treatment by recent clinical guidelines.1,6 However, endoscopic treatment for gastric varices (GV) is still challenging, and there is no consensus on the criterion for GV eradication or obliteration.To date, a standard endoscopic protocol integrating treatment for both EV and GV has not been established.Since over 80% of patients admitted for liver cirrhosis in tertiary healthcare centers present with high-risk esophagogastric varices (EGV) and require endoscopic therapy, 7 a standard but individualized endoscopic solution for treating both EV and GV is highly needed.Therefore, we herein introduce our systematic solution of endoscopic sequential therapy (EST) in terms of concept, performance and clinical efficacy.This solution integrates EV and GV treatment, emphasizes complete variceal eradication, and aims to sustain variceal remission and improve long-term prognosis.
No takes yet. Share an insight, caveat, or question.
Wang et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: